JPH1067663A5 - - Google Patents

Info

Publication number
JPH1067663A5
JPH1067663A5 JP1997162576A JP16257697A JPH1067663A5 JP H1067663 A5 JPH1067663 A5 JP H1067663A5 JP 1997162576 A JP1997162576 A JP 1997162576A JP 16257697 A JP16257697 A JP 16257697A JP H1067663 A5 JPH1067663 A5 JP H1067663A5
Authority
JP
Japan
Prior art keywords
mirtazapine
ssris
medicament
depression
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997162576A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1067663A (ja
JP4925074B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JPH1067663A publication Critical patent/JPH1067663A/ja
Publication of JPH1067663A5 publication Critical patent/JPH1067663A5/ja
Application granted granted Critical
Publication of JP4925074B2 publication Critical patent/JP4925074B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP16257697A 1996-06-19 1997-06-19 ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物 Expired - Fee Related JP4925074B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL96201703.4 1996-06-19
EP96201703 1996-06-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008317326A Division JP2009137970A (ja) 1996-06-19 2008-12-12 ミルタザピンと１種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物

Publications (3)

Publication Number Publication Date
JPH1067663A JPH1067663A (ja) 1998-03-10
JPH1067663A5 true JPH1067663A5 (https=) 2005-03-03
JP4925074B2 JP4925074B2 (ja) 2012-04-25

Family

ID=8224094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP16257697A Expired - Fee Related JP4925074B2 (ja) 1996-06-19 1997-06-19 ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
JP2008317326A Pending JP2009137970A (ja) 1996-06-19 2008-12-12 ミルタザピンと１種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008317326A Pending JP2009137970A (ja) 1996-06-19 2008-12-12 ミルタザピンと１種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物

Country Status (24)

Country Link
US (1) US5977099A (https=)
JP (2) JP4925074B2 (https=)
KR (1) KR100481254B1 (https=)
CN (1) CN1132581C (https=)
AR (1) AR007609A1 (https=)
AT (1) ATE213159T1 (https=)
AU (1) AU727851B2 (https=)
BR (1) BR9703624A (https=)
CA (1) CA2208199C (https=)
CZ (1) CZ290691B6 (https=)
DE (1) DE69710390T2 (https=)
DK (1) DK0813873T3 (https=)
ES (1) ES2172744T3 (https=)
HU (1) HU225534B1 (https=)
ID (1) ID17051A (https=)
IL (1) IL121076A (https=)
NO (1) NO313177B1 (https=)
NZ (1) NZ328113A (https=)
PL (1) PL188520B1 (https=)
PT (1) PT813873E (https=)
RU (1) RU2181287C2 (https=)
SG (1) SG60073A1 (https=)
TR (1) TR199700522A3 (https=)
ZA (1) ZA975335B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2001522891A (ja) * 1997-11-14 2001-11-20 アクゾ・ノベル・エヌ・ベー 睡眠時無呼吸を治療するためのミルタザピンの使用
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
AU780817B2 (en) * 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
BR0108261A (pt) * 2000-02-11 2003-03-05 Akzo Nobel Nv Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
KR100842694B1 (ko) * 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
KR101360698B1 (ko) 2009-06-09 2014-02-07 스미도모쥬기가이고교 가부시키가이샤 하이브리드식 쇼벨 및 그 제어방법
US8785453B2 (en) * 2009-11-13 2014-07-22 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物

Similar Documents

Publication Publication Date Title
JPH1067663A5 (https=)
RU97110083A (ru) Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
JP2003509343A5 (https=)
JP2004155791A5 (https=)
CA2387517A1 (en) Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
JP2007510736A5 (https=)
EP1435240A3 (en) Solid oral dosage form comprising a combination of methformin and glibenclamide
JP2004115529A5 (https=)
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
EP2266623A3 (en) Prodrugs containing novel bio-cleavable linkers
JP2009538276A5 (https=)
CA2386793A1 (en) New selective retinoid agonists
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
JP2002530341A5 (https=)
RU2009120115A (ru) Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом
JP2001513504A5 (https=)
JP2007505156A5 (https=)
DK1178780T3 (da) Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer
GEP20074225B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
JP2004529133A5 (https=)
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
RU2003132049A (ru) Фармацевтическая композиция, обладающая церебровазодилатирующей и ноотропной активностью
MXPA03001207A (es) Composicion farmaceutica que comprende un compuesto indol condensado.
JP2006160607A5 (https=)